Physician profile
Michael A Carter
NPI 1639293871
$4,158.57
in general payments reported to CMS, 2019-2025
34 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $457 · 2021: $656 · 2022: $732 · 2023: $755 · 2024: $719 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,178.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $353.59 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $243.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sunovion Pharmaceuticals INC. | $232.21 | 2019-2022 | |
| Lilly USA, LLC | $217.60 | 2019-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.89 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $141.89 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $116.53 | 2020-2024 | Austedo Xr, Austedo |
| Nestle Healthcare Nutrition INC. | $105.49 | 2021-2022 | |
| Mylan Specialty L.P. | $104.45 | 2022-2024 | Yupelri |
| Allergan, INC. | $97.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $96.68 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $91.62 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $89.42 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $75.58 | 2023-2025 | Rexulti |
| Pfizer INC. | $73.21 | 2019-2025 | |
| Axsome Therapeutics, INC. | $68.75 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $63.31 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sun Pharmaceutical Industries INC. | $62.20 | 2020-2021 | |
| Medtronic, INC. | $61.91 | 2021-2025 | Minimed 780g |
| Amgen INC. | $52.19 | 2020-2024 | Otezla, Repatha |
| Viatris Specialty LLC | $35.31 | 2025 | Yupelri |
| Verona Pharma, INC. | $26.97 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $24.02 | 2022 | |
| Neurocrine Biosciences, INC. | $23.99 | 2022 | |
| Abbott Laboratories | $23.44 | 2022 | |
| Neurelis, INC. | $20.74 | 2023 | Valtoco |
| Cmp Pharma, INC. | $20.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.15 | 2025 | Caplyta |
| Dexcom, INC. | $15.80 | 2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $15.21 | 2020 | |
| Glaxosmithkline, LLC. | $15.05 | 2024 | Trelegy Ellipta, Arexvy |
| Sanofi Pasteur INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.